BLAIR WILLIAM & CO/IL - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 155 filers reported holding REVANCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.4%.

Quarter-by-quarter ownership
BLAIR WILLIAM & CO/IL ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,742,730
-70.2%
326,306
-34.2%
0.01%
-69.6%
Q2 2023$12,560,720
+27.1%
496,275
+61.7%
0.05%
+17.9%
Q1 2023$9,884,508
+326.6%
306,877
+144.5%
0.04%
+290.0%
Q4 2022$2,316,822
-22.2%
125,505
+13.8%
0.01%
-28.6%
Q3 2022$2,978,000
+1419.4%
110,305
+677.2%
0.01%
+1300.0%
Q2 2022$196,000
-20.6%
14,193
+12.2%
0.00%0.0%
Q1 2022$247,000
+17.1%
12,651
-2.3%
0.00%0.0%
Q4 2021$211,000
-92.9%
12,951
-87.8%
0.00%
-90.0%
Q3 2021$2,960,000
+41.4%
106,231
+50.4%
0.01%
+42.9%
Q2 2021$2,094,000
+80.5%
70,634
+70.1%
0.01%
+75.0%
Q1 2021$1,160,000
+100.0%
41,514
+102.7%
0.00%
+100.0%
Q4 2020$580,000
+112.5%
20,481
+88.9%
0.00%
+100.0%
Q3 2020$273,000
-50.8%
10,841
-52.3%
0.00%
-66.7%
Q2 2020$555,000
+100.4%
22,736
+21.6%
0.00%
+50.0%
Q1 2020$277,000
+10.4%
18,700
+21.0%
0.00%
+100.0%
Q4 2019$251,000
-1.2%
15,450
+87.3%
0.00%
-50.0%
Q1 2018$254,000
-45.1%
8,250
-36.3%
0.00%
-33.3%
Q4 2017$463,000
-29.2%
12,950
-41.2%
0.00%
-50.0%
Q3 2015$654,00022,0070.01%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders